Alberto Alperi, Cesar Moris, Raquel Del Valle, Isaac Pascual, Paula Antuna, Marcel Almendárez, Daniel Hernández-Vaquero, Jose Luis Betanzos, Josep Rodés-Cabau, Pablo Avanzas
{"title":"自膨胀经导管主动脉瓣置换系统在瓣膜置入过程中的血液动力学性能。","authors":"Alberto Alperi, Cesar Moris, Raquel Del Valle, Isaac Pascual, Paula Antuna, Marcel Almendárez, Daniel Hernández-Vaquero, Jose Luis Betanzos, Josep Rodés-Cabau, Pablo Avanzas","doi":"10.25270/jic/23.00286","DOIUrl":null,"url":null,"abstract":"<p><strong>Objectives: </strong>Little is known about valve hemodynamic performance during the Evolut and Neo deployment course. We aimed to evaluate transvalvular mean and peak-to-peak gradients over several intraprocedural timepoints during TAVR with Evolut PRO+ (Medtronic) and Neo (Boston Scientific) systems.</p><p><strong>Methods: </strong>This was single-center pilot sub-study from the SavvyWire EFficacy and SafEty in Transcatheter Aortic Valve Implantation Procedures (SAFE-TAVI) trial. Participants received either the Evolut PRO+ or Neo for native valve severe aortic stenosis and the SavvyWire (OpSens Medical) was used for device delivery, pacing, and continuous left ventricular and aortic pressure measurements. For the Evolut, evaluation was done for baseline, two-thirds of valve deployment (still recapturable), 90% of valve deployment (no longer recapturable), and post-deployment hemodynamics. For the Neo, analysis was done at baseline, after the first step (top-crown deployment), and at final status.</p><p><strong>Results: </strong>Nineteen patients were included (Evolut = 15; Neo = 4). There were no statistically significant changes in peak-to-peak gradients (44 mm Hg [IQR:33-69] vs 43 mm Hg [IQR:26-62], P = .41) between baseline and two-thirds of valve deployment in the Evolut patients. There was a significant decrease in mean (40 mm Hg [IQR:32-54] vs 14 mm Hg [IQR:10-18], P less than .001) and peak-to-peak (43 mmHg [IQRS:26-62] vs 9 mm Hg [IQR:8-13], P less than .001) transvalvular gradients between two-thirds and 90% of valve deployment for Evolut. Neo patients exhibited a decrease in transvalvular gradients after top-crown deployment (42.5 mm Hg baseline vs 13 mm Hg).</p><p><strong>Conclusions: </strong>Transvalvular gradients did not vary between the point of \"no-recapture\" compared to baseline values in patients receiving the Evolut, whereas a significant reduction in transvalvular gradients was observed when the valve was deployed at 90% and fully deployed. The Neo valve was slightly obstructive after the first step of deployment.</p>","PeriodicalId":49261,"journal":{"name":"Journal of Invasive Cardiology","volume":" ","pages":""},"PeriodicalIF":1.6000,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Hemodynamic performance of self-expandable transcatheter aortic valve replacement systems during valve deployment.\",\"authors\":\"Alberto Alperi, Cesar Moris, Raquel Del Valle, Isaac Pascual, Paula Antuna, Marcel Almendárez, Daniel Hernández-Vaquero, Jose Luis Betanzos, Josep Rodés-Cabau, Pablo Avanzas\",\"doi\":\"10.25270/jic/23.00286\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Objectives: </strong>Little is known about valve hemodynamic performance during the Evolut and Neo deployment course. We aimed to evaluate transvalvular mean and peak-to-peak gradients over several intraprocedural timepoints during TAVR with Evolut PRO+ (Medtronic) and Neo (Boston Scientific) systems.</p><p><strong>Methods: </strong>This was single-center pilot sub-study from the SavvyWire EFficacy and SafEty in Transcatheter Aortic Valve Implantation Procedures (SAFE-TAVI) trial. Participants received either the Evolut PRO+ or Neo for native valve severe aortic stenosis and the SavvyWire (OpSens Medical) was used for device delivery, pacing, and continuous left ventricular and aortic pressure measurements. For the Evolut, evaluation was done for baseline, two-thirds of valve deployment (still recapturable), 90% of valve deployment (no longer recapturable), and post-deployment hemodynamics. For the Neo, analysis was done at baseline, after the first step (top-crown deployment), and at final status.</p><p><strong>Results: </strong>Nineteen patients were included (Evolut = 15; Neo = 4). There were no statistically significant changes in peak-to-peak gradients (44 mm Hg [IQR:33-69] vs 43 mm Hg [IQR:26-62], P = .41) between baseline and two-thirds of valve deployment in the Evolut patients. There was a significant decrease in mean (40 mm Hg [IQR:32-54] vs 14 mm Hg [IQR:10-18], P less than .001) and peak-to-peak (43 mmHg [IQRS:26-62] vs 9 mm Hg [IQR:8-13], P less than .001) transvalvular gradients between two-thirds and 90% of valve deployment for Evolut. Neo patients exhibited a decrease in transvalvular gradients after top-crown deployment (42.5 mm Hg baseline vs 13 mm Hg).</p><p><strong>Conclusions: </strong>Transvalvular gradients did not vary between the point of \\\"no-recapture\\\" compared to baseline values in patients receiving the Evolut, whereas a significant reduction in transvalvular gradients was observed when the valve was deployed at 90% and fully deployed. The Neo valve was slightly obstructive after the first step of deployment.</p>\",\"PeriodicalId\":49261,\"journal\":{\"name\":\"Journal of Invasive Cardiology\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":1.6000,\"publicationDate\":\"2024-08-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Invasive Cardiology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.25270/jic/23.00286\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"CARDIAC & CARDIOVASCULAR SYSTEMS\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Invasive Cardiology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.25270/jic/23.00286","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0
摘要
目的:我们对 Evolut 和 Neo 部署过程中的瓣膜血流动力学性能知之甚少。我们的目的是评估 Evolut PRO+ (美敦力)和 Neo(波士顿科学)系统在 TAVR 术中几个术中时间点的跨瓣膜平均梯度和峰-峰梯度:本研究是经导管主动脉瓣植入术(SavvyWire EFficacy and SafEty in Transcatheter Aortic Valve Implantation Procedures,SAFE-TAVI)试验的单中心试点子研究。参试者接受 Evolut PRO+ 或 Neo 治疗原生瓣膜重度主动脉瓣狭窄,SavvyWire(OpSens Medical)用于设备输送、起搏以及连续左心室和主动脉压力测量。对 Evolut 进行了基线、三分之二瓣膜部署(仍可再捕获)、90% 瓣膜部署(不再可再捕获)和部署后血液动力学评估。对于 Neo,则对基线、第一步(顶冠置入)后和最终状态进行了分析:共纳入 19 名患者(Evolut = 15;Neo = 4)。Evolut 患者的峰-峰梯度(44 mm Hg [IQR:33-69] vs 43 mm Hg [IQR:26-62], P = .41)在基线和瓣膜置入三分之二时的变化无统计学意义。Evolut 患者在瓣膜置入三分之二至 90% 期间,平均跨瓣梯度(40 mm Hg [IQR:32-54] vs 14 mm Hg [IQR:10-18],P 小于 0.001)和峰-峰梯度(43 mm Hg [IQRS:26-62] vs 9 mm Hg [IQR:8-13],P 小于 0.001)均明显下降。Neo患者在上冠置入后的跨瓣梯度有所下降(基线42.5 mm Hg vs 13 mm Hg):结论:与基线值相比,接受Evolut治疗的患者在 "无回声 "点之间的跨瓣梯度没有变化,而当瓣膜张开90%和完全张开时,跨瓣梯度明显降低。Neo瓣膜在第一步展开后略有阻塞。
Hemodynamic performance of self-expandable transcatheter aortic valve replacement systems during valve deployment.
Objectives: Little is known about valve hemodynamic performance during the Evolut and Neo deployment course. We aimed to evaluate transvalvular mean and peak-to-peak gradients over several intraprocedural timepoints during TAVR with Evolut PRO+ (Medtronic) and Neo (Boston Scientific) systems.
Methods: This was single-center pilot sub-study from the SavvyWire EFficacy and SafEty in Transcatheter Aortic Valve Implantation Procedures (SAFE-TAVI) trial. Participants received either the Evolut PRO+ or Neo for native valve severe aortic stenosis and the SavvyWire (OpSens Medical) was used for device delivery, pacing, and continuous left ventricular and aortic pressure measurements. For the Evolut, evaluation was done for baseline, two-thirds of valve deployment (still recapturable), 90% of valve deployment (no longer recapturable), and post-deployment hemodynamics. For the Neo, analysis was done at baseline, after the first step (top-crown deployment), and at final status.
Results: Nineteen patients were included (Evolut = 15; Neo = 4). There were no statistically significant changes in peak-to-peak gradients (44 mm Hg [IQR:33-69] vs 43 mm Hg [IQR:26-62], P = .41) between baseline and two-thirds of valve deployment in the Evolut patients. There was a significant decrease in mean (40 mm Hg [IQR:32-54] vs 14 mm Hg [IQR:10-18], P less than .001) and peak-to-peak (43 mmHg [IQRS:26-62] vs 9 mm Hg [IQR:8-13], P less than .001) transvalvular gradients between two-thirds and 90% of valve deployment for Evolut. Neo patients exhibited a decrease in transvalvular gradients after top-crown deployment (42.5 mm Hg baseline vs 13 mm Hg).
Conclusions: Transvalvular gradients did not vary between the point of "no-recapture" compared to baseline values in patients receiving the Evolut, whereas a significant reduction in transvalvular gradients was observed when the valve was deployed at 90% and fully deployed. The Neo valve was slightly obstructive after the first step of deployment.
期刊介绍:
The Journal of Invasive Cardiology will consider for publication suitable articles on topics pertaining to the invasive treatment of patients with cardiovascular disease.